Inmune Bio Stock Total Asset
| INMB Stock | USD 5.05 0.16 3.27% |
INmune Bio fundamentals help investors to digest information that contributes to INmune Bio's financial success or failures. It also enables traders to predict the movement of INmune Stock. The fundamental analysis module provides a way to measure INmune Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to INmune Bio stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 57 M | 41.6 M | |
| Intangibles To Total Assets | 0.29 | 0.56 |
INmune | Total Asset |
INmune Bio Company Total Asset Analysis
INmune Bio's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current INmune Bio Total Asset | 57 M |
Most of INmune Bio's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, INmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
INmune Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for INmune Bio is extremely important. It helps to project a fair market value of INmune Stock properly, considering its historical fundamentals such as Total Asset. Since INmune Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of INmune Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of INmune Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
INmune Total Asset Historical Pattern
Today, most investors in INmune Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various INmune Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of INmune Bio total asset as a starting point in their analysis.
INmune Bio Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
INmune Total Assets
Total Assets |
|
Based on the latest financial disclosure, INmune Bio has a Total Asset of 57 M. This is 99.24% lower than that of the Biotechnology sector and 97.12% lower than that of the Health Care industry. The total asset for all United States stocks is 99.81% higher than that of the company.
INmune Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses INmune Bio's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of INmune Bio could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics of similar companies.INmune Bio is currently under evaluation in total asset category among its peers.
INmune Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of INmune Bio from analyzing INmune Bio's financial statements. These drivers represent accounts that assess INmune Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of INmune Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 59.6M | 206.4M | 164.5M | 113.7M | 202.5M | 212.6M | |
| Enterprise Value | 52.8M | 184.6M | 105.0M | 76.8M | 177.1M | 185.9M |
INmune Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, INmune Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to INmune Bio's managers, analysts, and investors.Environmental | Governance | Social |
INmune Bio Institutional Holders
Institutional Holdings refers to the ownership stake in INmune Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of INmune Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing INmune Bio's value.| Shares | Renaissance Technologies Corp | 2024-09-30 | 107.2 K | Northern Trust Corp | 2024-09-30 | 96.8 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 92.1 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 79.9 K | Corton Capital Inc. | 2024-09-30 | 76.1 K | Royal Bank Of Canada | 2024-09-30 | 62.1 K | Bank Of New York Mellon Corp | 2024-09-30 | 49.6 K | Xtx Topco Ltd | 2024-09-30 | 46.3 K | Citadel Advisors Llc | 2024-09-30 | 46.1 K | Blackrock Inc | 2024-06-30 | 812.9 K | Praetorian Pr Llc | 2024-09-30 | 780.8 K |
INmune Fundamentals
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (989.21) % | ||||
| Current Valuation | 81.33 M | ||||
| Shares Outstanding | 22.17 M | ||||
| Shares Owned By Insiders | 28.72 % | ||||
| Shares Owned By Institutions | 24.34 % | ||||
| Number Of Shares Shorted | 3.57 M | ||||
| Price To Earning | (7.51) X | ||||
| Price To Book | 2.90 X | ||||
| Price To Sales | 2,666 X | ||||
| Revenue | 155 K | ||||
| Gross Profit | 374 K | ||||
| EBITDA | (29.74 M) | ||||
| Net Income | (30.01 M) | ||||
| Cash And Equivalents | 61.21 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 10.44 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 30.87 X | ||||
| Book Value Per Share | 1.74 X | ||||
| Cash Flow From Operations | (11.98 M) | ||||
| Short Ratio | 14.96 X | ||||
| Earnings Per Share | (2.18) X | ||||
| Target Price | 19.83 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.85 | ||||
| Market Capitalization | 111.97 M | ||||
| Total Asset | 57 M | ||||
| Retained Earnings | (121.02 M) | ||||
| Working Capital | 21.48 M | ||||
| Current Asset | 8.38 M | ||||
| Current Liabilities | 721.01 K | ||||
| Net Asset | 57 M |
About INmune Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out INmune Bio Piotroski F Score and INmune Bio Altman Z Score analysis. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.